Skip to content
TrialScanner

NCT05718817

An Open-label Study of XEN1101 in Epilepsy

Phase 3Enrolling by invitationXENELead

Registry record

Lead sponsor
Xenon Pharmaceuticals Inc.
Conditions
Focal Epilepsy; Tonic-Clonic Seizures
Primary completion
Apr 2033Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT05718817 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.